Zevra Therapeutics (NASDAQ:ZVRA) Price Target Cut to $18.00 by Analysts at JMP Securities

Zevra Therapeutics (NASDAQ:ZVRA) had its price target trimmed by JMP Securities from $19.00 to $18.00 in a report released on Wednesday,Benzinga reports. The firm currently has a market outperform rating on the stock.

Several other equities research analysts have also recently commented on the company. Cantor Fitzgerald upped their price target on Zevra Therapeutics from $25.00 to $29.00 and gave the stock an “overweight” rating in a research note on Thursday, July 10th. HC Wainwright initiated coverage on Zevra Therapeutics in a research note on Wednesday, July 2nd. They set a “buy” rating and a $26.00 price target for the company. Wall Street Zen downgraded shares of Zevra Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Sunday, July 20th. Finally, Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday. Nine investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $23.71.

Zevra Therapeutics Stock Performance

NASDAQ ZVRA opened at $9.43 on Wednesday. The company has a debt-to-equity ratio of 1.46, a current ratio of 3.02 and a quick ratio of 2.93. Zevra Therapeutics has a 1 year low of $6.19 and a 1 year high of $13.16. The company has a fifty day moving average of $10.55 and a two-hundred day moving average of $8.74. The company has a market capitalization of $515.63 million, a PE ratio of -44.90 and a beta of 1.87.

Zevra Therapeutics (NASDAQ:ZVRA) last released its earnings results on Tuesday, May 13th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.15. Zevra Therapeutics had a negative return on equity of 149.99% and a net margin of 4.33%. The business had revenue of $20.40 million for the quarter, compared to analyst estimates of $16.96 million. During the same quarter in the previous year, the company posted ($0.40) earnings per share. As a group, analysts expect that Zevra Therapeutics will post -1.95 earnings per share for the current year.

Institutional Investors Weigh In On Zevra Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Ameritas Investment Partners Inc. lifted its position in shares of Zevra Therapeutics by 30.0% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 5,541 shares of the company’s stock valued at $49,000 after acquiring an additional 1,280 shares during the period. BNP Paribas Financial Markets acquired a new stake in shares of Zevra Therapeutics during the 4th quarter valued at approximately $53,000. GAMMA Investing LLC lifted its position in shares of Zevra Therapeutics by 20,564.1% during the 1st quarter. GAMMA Investing LLC now owns 8,059 shares of the company’s stock valued at $60,000 after acquiring an additional 8,020 shares during the period. Creative Planning acquired a new stake in shares of Zevra Therapeutics during the 2nd quarter valued at approximately $92,000. Finally, Fox Run Management L.L.C. acquired a new stake in shares of Zevra Therapeutics during the 2nd quarter valued at approximately $99,000. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.